Goldman Sachs has initiated coverage on medical equipment maker ResMed and biotech giant CSL with a ‘buy’ ratings as analysts ...

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Based in San Diego, California, ResMed Inc. (RMD) develops, manufactures, distributes, and markets medical devices and ...

RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered ...

Imagine looking at your selfie and finding a number that represents your biological age — finding out how old your body feels, rather than what the calendar says. This interesting concept, known as ...

Samantha Kelly is a freelance writer with a focus on consumer technology, AI, social media, Big Tech, emerging trends and how they impact our everyday lives. Her work has been featured on CNN, NBC ...

ResMed shares slumped and Eli Lilly shares gained after the FDA approved Eli Lilly's weight-loss treatment Zepbound for some patients with sleep apnea. Major U.S. indexes were mixed at midday ...